Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | RHOC | P08134 | 5/20 | 0.34 |
| ▸ | RHOA | P61586 | 5/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921105 | 0.92 | HDAC6 (0.37) | MAPTKCNJ11CHEK1LMNAHDAC6 | |
| SCHEMBL9920876 | 0.90 | LMNA (0.33) | MAPTCHEK1MEN1LMNAPOLB | |
| SCHEMBL9920877 | 0.86 | MEN1 (0.36) | RAB9ACYP1A2CYP2D6CYP2C19MAPT | |
| SCHEMBL17509141 | 0.86 | MEN1 (0.36) | RAB9ACYP1A2CYP2D6CYP2C19MAPT | |
| SCHEMBL9921121 | 0.83 | IDO1 (0.38) | RAB9ACYP1A2CYP2D6CYP2C19MAPT | |
| SCHEMBL19360246 | 0.83 | STK25 (0.39) | RAB9ACYP1A2CYP2D6CYP2C19MAPT | |
| SCHEMBL9905331 | 0.82 | HPGD (0.35) | RAB9ACYP1A2CYP2D6CYP2C19MAPT | |
| SCHEMBL9905335 | 0.82 | HPGD (0.35) | RAB9ACYP1A2CYP2D6CYP2C19MAPT | |
| SCHEMBL17088583 | 0.82 | EPHX2 (0.46) | KMT2AHDAC6 | |
| SCHEMBL18558418 | 0.82 | HDAC6 (0.37) | MAPTCHEK1LMNAPOLBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| EP-2648511-B1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2012078874-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | RAB9A 519/4885CYP1A2 1569/4885CYP2D6 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.